Bicycle Therapeutics (BCYC) Enterprise Value (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Enterprise Value came in at -$510.1 million in Q2 2026, up 29.3% YoY from -$394.5 million in Q2 2025, and up 8.83% on a QoQ basis from -$559.5 million in Q1 2026.
Bicycle Therapeutics (BCYC) Enterprise Value (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Enterprise Value data on file, last reported at -$510.1 million in Q2 2026.
- Quarterly Enterprise Value rose 29.3% year-over-year to -$510.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$510.1 million (up 29.3% YoY) and the FY2025 annual result came in at -$628.1 million, up 28.58% from the prior year.
- Enterprise Value rose to -$510.1 million in Q2 2026, from -$559.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$293.8 million in Q1 2023 to a low of -$961.4 million in Q2 2024.
- A 5-year average of -$570.2 million and a median of -$543.0 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value sank 182.39% — and 2026, when it rose 29.44%.
- Tracing BCYC's Enterprise Value over 5 years: stood at -$339.2 million in 2022, then plunged by 55.22% to -$526.4 million in 2023, then sank by 67.07% to -$879.5 million in 2024, then advanced by 28.58% to -$628.1 million in 2025, then gained by 18.79% to -$510.1 million in 2026.
- The last three Enterprise Value figures came in at -$510.1 million (Q2 2026), -$559.5 million (Q1 2026), and -$628.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | -510.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -510.10 Mn |
| Mar 31, 2026 | -559.47 Mn |
| Dec 31, 2025 | -628.11 Mn |
| Sep 30, 2025 | -648.30 Mn |
| Jun 30, 2025 | -721.50 Mn |
| Mar 31, 2025 | -792.97 Mn |
| Dec 31, 2024 | -664.90 Mn |
| Sep 30, 2024 | -890.86 Mn |
| Jun 30, 2024 | -961.36 Mn |
| Mar 31, 2024 | -457.00 Mn |
| Dec 31, 2023 | -526.42 Mn |
| Sep 30, 2023 | -572.09 Mn |
| Jun 30, 2023 | -340.43 Mn |
| Mar 31, 2023 | -293.82 Mn |
| Dec 31, 2022 | -339.15 Mn |
| Sep 30, 2022 | -361.47 Mn |
| Jun 30, 2022 | -372.80 Mn |
| Mar 31, 2022 | -100.00 Mn |
| Dec 31, 2021 | -438.68 Mn |
| Sep 30, 2021 | -259.52 Mn |